MCID: EWN002
MIFTS: 57

Ewing's Family of Tumors

Categories: Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Ewing's Family of Tumors

MalaCards integrated aliases for Ewing's Family of Tumors:

Name: Ewing's Family of Tumors 54
Primitive Neuroectodermal Tumor 54 6 17
Neuroectodermal Tumor, Primitive 74
Ewing Family of Tumors 54

Classifications:



External Ids:

UMLS 74 C0206663

Summaries for Ewing's Family of Tumors

MalaCards based summary : Ewing's Family of Tumors, also known as primitive neuroectodermal tumor, is related to extraskeletal ewing sarcoma and neurofibroma. An important gene associated with Ewing's Family of Tumors is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are GPCR Pathway and PEDF Induced Signaling. The drugs Pancrelipase and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Ewing's Family of Tumors

Diseases related to Ewing's Family of Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 244)
# Related Disease Score Top Affiliating Genes
1 extraskeletal ewing sarcoma 30.6 EWSR1 FLI1
2 neurofibroma 30.4 CDKN2A KIT KITLG
3 gastrointestinal stromal tumor 30.1 CDKN2A KIT KITLG
4 ewing sarcoma 30.0 CDK4 CDKN2A CSF3 EWSR1 FAS FLI1
5 squamous cell carcinoma 29.7 CDKN2A ERBB2 FAS RB1
6 glioblastoma multiforme 29.5 CDK4 CDKN2A ERBB2 MTOR RB1
7 glioblastoma 29.4 CDK4 CDKN2A CDKN2B ERBB2 MTOR RB1
8 leukemia, acute myeloid 28.9 CDKN2B CSF3 KIT KITLG MTOR
9 myelodysplastic syndrome 28.6 CDKN2B CSF3 EPO EPOR FAS KIT
10 sarcoma 28.6 CDK4 EWSR1 FLI1 KIT MTOR RB1
11 supratentorial primitive neuroectodermal tumor 12.7
12 cerebral primitive neuroectodermal tumor 12.6
13 primitive neuroectodermal tumor of the cervix uteri 12.5
14 intracranial primitive neuroectodermal tumor 12.4
15 supratentorial primitive neuroectodermal tumors, childhood 12.4
16 primitive neuroectodermal tumor of the corpus uteri 12.4
17 medulloblastoma 12.3
18 bone ewing's sarcoma 12.0
19 pineoblastoma 11.8
20 spinal cord primitive neuroectodermal neoplasm 11.7
21 extraosseous ewing's sarcoma 11.7
22 cerebellopontine angle primitive neuroectodermal 11.7
23 bone peripheral neuroepithelioma 11.7
24 atypical teratoid rhabdoid tumor 11.7
25 askin's tumor 11.7
26 ependymoblastoma 11.7
27 pineoblastoma, childhood 11.7
28 rhabdoid tumor predisposition syndrome 1 11.5
29 adult central nervous system primitive neuroectodermal neoplasm 11.4
30 childhood central nervous system primitive neuroectodermal neoplasm 11.4
31 rhabdoid tumor predisposition syndrome 2 11.4
32 spindle cell sarcoma 10.6
33 teratoma 10.6
34 rhabdoid cancer 10.5
35 heparin-induced thrombocytopenia 10.4
36 germ cells tumors 10.4
37 cellular myxoid liposarcoma 10.4 CDK4 EWSR1
38 infiltrating angiolipoma 10.4 CDK4 CDKN2A
39 leukemia 10.4
40 breast papillomatosis 10.4 CDKN2A ERBB2
41 cornea cancer 10.4 CDK4 CDKN2A
42 tenosynovial giant cell tumor 10.4 CDKN2A CDKN2B
43 scrotal carcinoma 10.4 CDKN2A CDKN2B
44 fallopian tube endometrioid adenocarcinoma 10.4 CDKN2A ERBB2
45 atypical lipomatous tumor 10.3 CDK4 CDKN2A
46 myxoid chondrosarcoma 10.3 CDKN2B EWSR1
47 vulval paget's disease 10.3 CDKN2A ERBB2
48 lymphoma 10.3
49 cystic teratoma 10.3
50 glioma 10.3

Graphical network of the top 20 diseases related to Ewing's Family of Tumors:



Diseases related to Ewing's Family of Tumors

Symptoms & Phenotypes for Ewing's Family of Tumors

GenomeRNAi Phenotypes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

27 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.17 KIT
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.17 EWSR1 MTOR
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.17 MTOR
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.17 CDK4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.17 CDK4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.17 EWSR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.17 EWSR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.17 EWSR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.17 EWSR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.17 EWSR1 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.17 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.17 MTOR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.17 EWSR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.17 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.17 EWSR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.17 CDK4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.17 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.17 CDK4 EWSR1 KIT MTOR
19 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.17 CDK4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.17 EWSR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.17 MTOR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.17 EWSR1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.17 CDK4 KIT MTOR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.17 KIT
25 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.17 EWSR1 KIT
26 Decreased substrate adherent cell growth GR00193-A-1 9.7 KIT
27 Decreased substrate adherent cell growth GR00193-A-2 9.7 CDK4 KIT MTOR
28 Decreased substrate adherent cell growth GR00193-A-3 9.7 CDK4
29 Decreased substrate adherent cell growth GR00193-A-4 9.7 CDK4 KIT
30 Increased transferrin (TF) endocytosis GR00363-A 9.32 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2

MGI Mouse Phenotypes related to Ewing's Family of Tumors:

47 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
2 cardiovascular system MP:0005385 10.35 CDK4 CDKN2A EPO EPOR ERBB2 FAS
3 hematopoietic system MP:0005397 10.35 CDK4 CDKN2A CDKN2B CSF3 EPO EPOR
4 immune system MP:0005387 10.33 CDK4 CDKN2A CDKN2B CSF3 EPO EPOR
5 homeostasis/metabolism MP:0005376 10.3 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
6 embryo MP:0005380 10.29 CDK4 CDKN2A EPO EPOR ERBB2 FLI1
7 endocrine/exocrine gland MP:0005379 10.28 CDK4 CDKN2A CDKN2B ERBB2 FAS FLI1
8 growth/size/body region MP:0005378 10.27 CDK4 CDKN2A EPOR ERBB2 FAS FLI1
9 mortality/aging MP:0010768 10.27 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
10 integument MP:0010771 10.24 CDK4 CDKN2A CDKN2B CSF3 EPO ERBB2
11 liver/biliary system MP:0005370 10.16 CDK4 CDKN2A EPO EPOR FAS FLI1
12 digestive/alimentary MP:0005381 10.14 CDK4 CDKN2A ERBB2 FAS KIT KITLG
13 nervous system MP:0003631 10.13 CDK4 CDKN2A EPOR ERBB2 FAS FLI1
14 neoplasm MP:0002006 10.11 CDK4 CDKN2A CDKN2B ERBB2 FAS FLI1
15 muscle MP:0005369 10.08 CDK4 CDKN2A EPO ERBB2 FLI1 KIT
16 limbs/digits/tail MP:0005371 10 EPO ERBB2 FAS KIT KITLG RB1
17 normal MP:0002873 9.97 CDK4 EPO EPOR ERBB2 FAS KIT
18 no phenotypic analysis MP:0003012 9.88 CDKN2A CDKN2B EPOR KIT MTOR RB1
19 pigmentation MP:0001186 9.8 CDK4 CDKN2A FAS KIT KITLG RB1
20 renal/urinary system MP:0005367 9.8 CDK4 CDKN2B CSF3 FAS KIT MTOR
21 reproductive system MP:0005389 9.76 CDK4 CDKN2A CDKN2B ERBB2 FAS KIT
22 respiratory system MP:0005388 9.56 CDKN2A EPO EPOR ERBB2 FAS KIT
23 skeleton MP:0005390 9.23 CDKN2A EPO ERBB2 FAS KIT KITLG

Drugs & Therapeutics for Ewing's Family of Tumors

Drugs for Ewing's Family of Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1026)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
3
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
4
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 85622-93-1 5394
5
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
6
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
7
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 53643-48-4, 59917-39-4 40839
8
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-03-3
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
10
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-23-7 5754
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
12
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 5284616 6436030
13
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 70789204 6442177
14
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
15
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 38916-34-6, 51110-01-1 53481605
16
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
17
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
18
Carboplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 38904 498142
19
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
20
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
21
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
22
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 83150-76-9 6400441 383414
23
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
24
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
25
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
26
Mesna Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 3375-50-6 598
27
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
28
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 52-24-4 5453
29
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
30
Levetiracetam Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 102767-28-2 441341
31
Pembrolizumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 1374853-91-4
32
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
33
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
34
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 477202-00-9
35
Vemurafenib Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 918504-65-1 23252090 42611257
36
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
37
Palbociclib Approved, Investigational Phase 4,Phase 1,Phase 2 571190-30-2 5005498 11431660 5330286
38
Ceritinib Approved Phase 4,Phase 2,Phase 1,Early Phase 1 1032900-25-6
39
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
40
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 110942-02-4, 85898-30-2
41
Racepinephrine Approved Phase 4,Phase 2,Phase 1,Not Applicable 329-65-7 838
42
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 51-43-4 5816
43
Itraconazole Approved, Investigational Phase 4,Phase 1 84625-61-6 55283
44
Etanercept Approved, Investigational Phase 4,Phase 2 185243-69-0
45
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
46
Phenoxybenzamine Approved Phase 4,Phase 3 59-96-1 4768
47
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
48
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99-66-1 3121
49
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1195765-45-7 44462760 44516822
50
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444

Interventional clinical trials:

(show top 50) (show all 5336)
# Name Status NCT ID Phase Drugs
1 Nonfunctional Pancreatic NET and PET Imaging Unknown status NCT02621541 Phase 4
2 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
3 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
4 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
5 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
6 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Unknown status NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
7 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
8 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
9 Radiolabeled Molecules for Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
10 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
11 An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) Completed NCT01595009 Phase 4 Everolimus (RAD001)
12 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
13 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
14 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Completed NCT02075606 Phase 4 lanreotide acetate
15 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01525550 Phase 4 sunitinib
16 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4 carboplatin periocular injection;CEV chemotherapy
17 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
18 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
19 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
20 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
21 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
22 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
23 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
24 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
25 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
26 Dolutegravir and Darunavir Evaluation in Adults Failing Therapy Recruiting NCT03017872 Phase 4 NRTIs;Dolutegravir;Darunavir;Ritonavir
27 A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Recruiting NCT03289741 Phase 4 Octreotide;LAR Lanreotide
28 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Recruiting NCT03083210 Phase 4 Lanreotide
29 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
30 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4 Induction;Single Cycle Intensive Chemotherapy;Tandem 3 Cycle Intensive Chemotherapy
31 Seizure Treatment in Glioma Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
32 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
33 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
34 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
35 Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Recruiting NCT03715205 Phase 4 Pembrolizumab
36 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
37 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
38 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
39 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Active, not recruiting NCT02842749 Phase 4 everolimus
40 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
41 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
42 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
43 Body Composition Sub-study of the D2EFT Trial Not yet recruiting NCT03675815 Phase 4 Darunavir 800 MG Oral Tablet;Ritonavir 100 MG Oral Tablet;N(t)RTIs;Dolutegravir 50 MG Oral Tablet;TDF 300 MG Oral Tablet;3TC 300 MG Oral Tablet;FTC 200 MG Oral Cap
44 Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies Not yet recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
45 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
46 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
47 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
48 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
49 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
50 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide

Search NIH Clinical Center for Ewing's Family of Tumors

Genetic Tests for Ewing's Family of Tumors

Anatomical Context for Ewing's Family of Tumors

MalaCards organs/tissues related to Ewing's Family of Tumors:

42
Brain, T Cells, Lung, Bone, Liver, Thyroid, Kidney

Publications for Ewing's Family of Tumors

Articles related to Ewing's Family of Tumors:

(show top 50) (show all 892)
# Title Authors Year
1
Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. ( 31104192 )
2019
2
Pazopanib Confers a Progression-free Survival in a Patient with Ewing's Sarcoma/Primitive Neuroectodermal Tumor of the Lung. ( 30626819 )
2019
3
Atypical presentation of a germline APC mutation in a child with supratentorial primitive neuroectodermal tumor. ( 30511453 )
2019
4
Qualitative and quantitative CECT features for differentiating renal primitive neuroectodermal tumor from the renal cell carcinoma and its subtypes. ( 30362816 )
2019
5
Peripheral primitive neuroectodermal tumor associated with paraneoplastic Cushing's syndrome: The rare case. ( 30581565 )
2019
6
Long-term survival of a patient with a large adrenal primitive neuroectodermal tumor: A case report. ( 30746375 )
2019
7
Primitive neuroectodermal tumor of kidney with Level III inferior vena cava thrombus. ( 30787583 )
2019
8
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor in the Adrenal Gland of a Child. ( 29891750 )
2018
9
Renal Ewing sarcoma/primitive neuroectodermal tumor in a pregnant woman who underwent robot-assisted laparoscopic nephrectomy: a case report and literature review. ( 30349316 )
2018
10
Extraosseous Primary Intracranial Ewing Sarcoma/peripheral Primitive Neuroectodermal Tumor: Series of Seven Cases and Review of Literature. ( 29682023 )
2018
11
Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. ( 28429277 )
2018
12
A k-mer based transcriptomics approach for antisense drug discovery targeting the Ewing's family of tumors. ( 30093970 )
2018
13
Glioblastoma with Both Oligodendroglioma and Primitive Neuroectodermal Tumor-Like Components in a Case with 9-Year Survival. ( 29992076 )
2018
14
Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: Case report and review of the literature. ( 29616127 )
2018
15
Is there an increased risk of spinal relapse in standard-risk medulloblastoma/primitive neuroectodermal tumor patients who receive only a reduced dose of craniospinal radiotherapy? ( 29868932 )
2018
16
Thyroid dysfunction in patients with childhood-onset medulloblastoma or primitive neuroectodermal tumor. ( 29969880 )
2018
17
Ewing-Like Sarcoma: A Case of a Primary Cutaneous Primitive Neuroectodermal Tumor With Atypical Immunohistochemistry and Lack of Fusion Oncogene Detection. ( 30067549 )
2018
18
Case report of an ewing's sarcoma/primitive neuroectodermal tumor of the kidney. ( 29946819 )
2018
19
A mesenteric primary peripheral Ewing's sarcoma/primitive neuroectodermal tumor with molecular cytogenetic analysis: Report of a rare case and review of literature. ( 29676369 )
2018
20
A rare case of Ewing's sarcoma/primitive neuroectodermal tumor metastasizing to left atrium through left inferior pulmonary vein. ( 29676474 )
2018
21
Integrated bioinformatic analysis unveils significant genes and pathways in the pathogenesis of supratentorial primitive neuroectodermal tumor. ( 29670360 )
2018
22
Primitive neuroectodermal tumor transformation of testicular teratoma. ( 30386097 )
2018
23
Primary Paediatric Renal Primitive Neuroectodermal Tumor: A Case Report and Review of the Literature. ( 28272661 )
2018
24
Lumbosacral Epidural Primitive Neuroectodermal Tumor (PNET): Case Report and Literature Review. ( 28383090 )
2018
25
Metastatic Primitive Neuroectodermal Tumor of the Prostate: A Case Report and Review of the Literature. ( 29239847 )
2018
26
A primitive neuroectodermal tumor in an adult: Case report of a unique location and MRI characteristics. ( 29443778 )
2018
27
Primary primitive neuroectodermal tumor of the kidney. ( 29676370 )
2018
28
Peripheral primitive neuroectodermal tumor of cauda equina: A report and review of literature. ( 29766958 )
2018
29
Primitive neuroectodermal tumor of the kidney at the advanced stage: A case series of eight Chinese patients. ( 29805790 )
2018
30
Detection of cavernous malformations after whole-brain radiotherapy in primitive neuroectodermal tumor patients-comparing susceptibility-weighted imaging and T2 gradient-echo sequences. ( 30030548 )
2018
31
Adjuvant chemotherapy for a primitive neuroectodermal tumor of the uterine corpus: A case report and literature review. ( 30051552 )
2018
32
Successful Novel Treatment of a Paraspinal Primitive Neuroectodermal Tumor with Predominantly Glial Differentiation: A 3-Year Follow-Up After Surgery, Intensity-Modulated Radiation Therapy and Oral Temozolomide. ( 30077020 )
2018
33
Primitive neuroectodermal tumor of the kidney: A rare case report. ( 30078975 )
2018
34
Intraspinal Intramedullary Primitive Neuroectodermal Tumor in a Young Girl: A Case Report from BSMMU, Bangladesh. ( 30141462 )
2018
35
Intracranial Peripheral Primitive Neuroectodermal Tumor Arising from the Clivus with Intracranial Metastasis in an Elderly Woman: Case Report and Review of the Literature. ( 30144615 )
2018
36
The outcome of Pregnancy with Fetal Primitive Neuroectodermal Tumor. ( 30159075 )
2018
37
Primitive neuroectodermal tumor of genital tract in hysterectomized patient: A case report. ( 30202633 )
2018
38
Pancreatic primitive neuroectodermal tumor: Focus on radiological features and differential diagnosis - A case report and literature review. ( 30249906 )
2018
39
Primitive neuroectodermal tumor arising from an untreated congenital undescended testicle. ( 30281013 )
2018
40
Ovarian Transposition in a Young Girl with Primitive Neuroectodermal Tumor of Bladder. ( 30288013 )
2018
41
Scrotal Peripheral Primitive Neuroectodermal Tumor. ( 30374281 )
2018
42
A Rare Case of Dumbbell-shaped Primary Intraspinal Peripheral Primitive Neuroectodermal Tumor Involving Thoracic Spinal Epidural Space. ( 30459898 )
2018
43
Primary spinal primitive neuroectodermal tumor: A single center series with literature review. ( 30561250 )
2018
44
Cervicomedullary primitive neuroectodermal tumor of the spine: Case report. ( 30595962 )
2018
45
Peripheral Primitive Neuroectodermal Tumor of the Ovary: The Report of Two Rare Cases. ( 30774687 )
2018
46
Primary Primitive Neuroectodermal Tumor Arising from an Ovarian Mature Cystic Teratoma in a 12-Year-Old Girl: A Case Report. ( 27919713 )
2017
47
Rare Ileal Ewing Sarcoma/Primitive Neuroectodermal Tumor on 18F-FDG PET/CT. ( 28806254 )
2017
48
Primary intracranial dural-based Ewing sarcoma/peripheral primitive neuroectodermal tumor mimicking a meningioma: A rare tumor with review of literature. ( 28761507 )
2017
49
Malignant glioma-primitive neuroectodermal tumor recurring as PNET-like only subdural collection: Case report. ( 29119041 )
2017
50
Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive neuroectodermal tumor cells to chemotherapeutic cytotoxicity. ( 28877739 )
2017

Variations for Ewing's Family of Tumors

Expression for Ewing's Family of Tumors

Search GEO for disease gene expression data for Ewing's Family of Tumors.

Pathways for Ewing's Family of Tumors

Pathways related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 CDK4 CDKN2A CDKN2B EPOR ERBB2 KIT
2
Show member pathways
13.58 CSF3 EPO EPOR ERBB2 FAS KIT
3
Show member pathways
13.53 CDK4 CDKN2A CDKN2B CSF3 EPOR ERBB2
4
Show member pathways
13.28 CSF3 EPOR ERBB2 FAS KIT KITLG
5
Show member pathways
13.04 CDK4 CDKN2A CDKN2B EPO MTOR RB1
6
Show member pathways
12.88 CDK4 CDKN2A FAS MTOR RB1
7
Show member pathways
12.84 EPO EPOR FAS KIT KITLG
8
Show member pathways
12.72 CDK4 CDKN2A ERBB2 KIT MTOR RB1
9 12.67 ERBB2 FAS KIT KITLG
10
Show member pathways
12.64 ERBB2 KIT KITLG MTOR
11
Show member pathways
12.53 CDK4 CDKN2A CDKN2B ERBB2 MTOR RB1
12
Show member pathways
12.49 CDK4 CDKN2A CDKN2B RB1
13
Show member pathways
12.49 CDK4 CSF3 EPO EPOR ERBB2 FAS
14 12.48 FAS FLI1 KIT KITLG
15
Show member pathways
12.47 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
16
Show member pathways
12.33 CSF3 EPO EPOR MTOR
17
Show member pathways
12.3 CDK4 CDKN2A FAS RB1
18
Show member pathways
12.3 EPOR ERBB2 KIT KITLG MTOR
19 12.29 CDK4 CDKN2A CDKN2B RB1
20
Show member pathways
12.27 CDK4 CDKN2A CDKN2B RB1
21 12.23 CDK4 CDKN2A CDKN2B KITLG RB1
22 12.2 CDK4 CDKN2A CDKN2B RB1
23
Show member pathways
12.14 CDK4 ERBB2 MTOR RB1
24
Show member pathways
12.11 CDK4 CDKN2A CDKN2B RB1
25 12.09 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
26 12.06 CDK4 MTOR RB1
27
Show member pathways
12.06 EPO EPOR KIT KITLG
28 12.04 ERBB2 KIT KITLG
29 12.01 CDK4 CDKN2A CDKN2B MTOR RB1
30 11.89 CSF3 EPO KIT KITLG
31 11.88 CDKN2A MTOR RB1
32 11.86 CDK4 CDKN2A MTOR RB1
33 11.84 EPO ERBB2 MTOR
34 11.81 EPO EPOR MTOR
35 11.81 CDK4 CDKN2B RB1
36 11.68 CDKN2A ERBB2 FAS
37 11.64 CDK4 MTOR RB1
38 11.61 ERBB2 KIT MTOR
39 11.6 CDK4 CDKN2A ERBB2 RB1
40 11.54 CSF3 EPO EPOR KIT KITLG
41 11.47 CDKN2A FAS RB1
42 11.43 EPO KIT KITLG
43 11.4 CDK4 CDKN2B RB1
44 11.35 CSF3 EPO FLI1 KITLG
45 11.22 CDK4 CDKN2A CDKN2B
46 11.04 CDKN2A RB1
47 10.94 CSF3 EPOR ERBB2 KIT KITLG
48 10.89 KIT KITLG

GO Terms for Ewing's Family of Tumors

Biological processes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.89 CDKN2A ERBB2 KIT MTOR
2 positive regulation of cell proliferation GO:0008284 9.83 CDK4 CSF3 EPO KIT KITLG
3 G1/S transition of mitotic cell cycle GO:0000082 9.7 CDK4 CDKN2A RB1
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 CSF3 KITLG MTOR
5 negative regulation of apoptotic process GO:0043066 9.63 EPO FAS KITLG
6 positive regulation of Ras protein signal transduction GO:0046579 9.58 EPO KITLG
7 negative regulation of phosphorylation GO:0042326 9.58 CDKN2A CDKN2B
8 positive regulation of translation GO:0045727 9.58 CDK4 ERBB2 MTOR
9 embryonic hemopoiesis GO:0035162 9.57 KIT KITLG
10 megakaryocyte development GO:0035855 9.56 FLI1 KIT
11 response to hyperoxia GO:0055093 9.55 CDK4 EPO
12 positive regulation of MAP kinase activity GO:0043406 9.5 ERBB2 KIT KITLG
13 somatic stem cell division GO:0048103 9.48 CDKN2A KIT
14 cell cycle arrest GO:0007050 9.46 CDKN2A CDKN2B MTOR RB1
15 ectopic germ cell programmed cell death GO:0035234 9.37 KIT KITLG
16 positive regulation of protein kinase B signaling GO:0051897 9.35 CSF3 ERBB2 KIT KITLG MTOR
17 negative regulation of immature T cell proliferation in thymus GO:0033088 9.26 CDKN2A ERBB2
18 positive regulation of transcription by RNA polymerase III GO:0045945 9.21 MTOR
19 erythropoietin-mediated signaling pathway GO:0038162 8.8 EPO EPOR KIT
20 signal transduction GO:0007165 10.08 CDK4 EPO EPOR ERBB2 FAS KIT

Molecular functions related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.97 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
2 nucleotide binding GO:0000166 9.56 CDK4 ERBB2 KIT MTOR
3 identical protein binding GO:0042802 9.1 EPOR ERBB2 EWSR1 FAS MTOR RB1
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.96 CDKN2A CDKN2B

Sources for Ewing's Family of Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....